Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 13/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 8/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 6/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 4/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 0.63 |
| ▸ | ABL1 | P00519 | 2/20 | 0.63 |
| ▸ | INSR | P06213 | 2/20 | 0.63 |
| ▸ | LCK | P06239 | 2/20 | 0.63 |
| ▸ | FYN | P06241 | 2/20 | 0.63 |
| ▸ | YES1 | P07947 | 2/20 | 0.63 |
| ▸ | LYN | P07948 | 2/20 | 0.63 |
| ▸ | RET | P07949 | 2/20 | 0.63 |
| ▸ | MET | P08581 | 2/20 | 0.63 |
| ▸ | ROS1 | P08922 | 2/20 | 0.63 |
| ▸ | KIT | P10721 | 2/20 | 0.63 |
| ▸ | SRC | P12931 | 2/20 | 0.63 |
| ▸ | BRAF | P15056 | 2/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.63 |
| ▸ | FLT1 | P17948 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363673 | 1.00 | FGFR1 (1.00) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL19441967 | 0.92 | FGFR3 (0.84) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL19753756 | 0.90 | FGFR3 (0.82) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL374413 | 0.86 | FGFR3 (0.81) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL583166 | 0.82 | FGFR3 (0.86) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL20867981 | 0.82 | FGFR1 (0.69) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL20867713 | 0.82 | FGFR1 (0.69) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL374643 | 0.82 | FGFR3 (0.72) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL19507407 | 0.81 | FGFR4 (0.75) | FGFR1FGFR3FGFR4FGFR2EGFR | |
| SCHEMBL2017841 | 0.81 | FGFR3 (0.84) | FGFR1FGFR3FGFR4FGFR2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-10906878-B2 | Kinase inhibitors for the treatment of disease | DANA FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190256475-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10316002-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170369449-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256475-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | FGFR1 27/4885FGFR3 21/4885FGFR4 40/4885 |
| US-20170369449-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | FGFR1 27/4885FGFR3 21/4885FGFR4 40/4885 |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | FGFR1 1/4885FGFR3 13/4885FGFR4 8/4885 |
| US-10906878-B2 | Kinase inhibitors for the treatment of disease | BLK, ROS1, TEC | FGFR1 27/4885FGFR3 21/4885FGFR4 40/4885 |
| US-10316002-B2 | Kinase inhibitors for the treatment of disease | BLK, ROS1, TEC | FGFR1 27/4885FGFR3 21/4885FGFR4 40/4885 |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | FGFR1 27/4885FGFR3 21/4885FGFR4 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.